The global varicella vaccines market is poised for moderate growth, with revenue expected to rise from USD 3,258.6 million in 2024 to USD 4,115.4 million by 2034, reflecting a CAGR of 2.4% during the forecast period. This growth is primarily driven by heightened public awareness of the effectiveness of varicella vaccines, supported by government initiatives and vaccination campaigns aimed at reducing the incidence of the highly contagious disease.
Varicella, commonly known as chickenpox, remains a prevalent concern in many regions, particularly in densely populated areas where the risk of infection is higher. In response to this, various governments and public health organizations have launched vaccination programs to curb the spread of the disease, significantly contributing to the growing demand for varicella vaccines. Increased recognition of the long-term health benefits of vaccination has also driven the adoption of varicella vaccines, contributing to a decline in the number of severe cases.
Moreover, the rising incidence of varicella infections in certain regions continues to push demand for widespread vaccination. As the global focus on immunization programs strengthens, more individuals are seeking vaccination as a preventive measure. This trend, combined with the ongoing efforts to ensure global access to vaccines, will further expand the market for varicella vaccines over the next decade.
The varicella vaccines market presents opportunities for vaccine manufacturers, healthcare providers, and public health organizations. As the demand for effective immunization continues to grow, the market is expected to experience steady development, with significant contributions from ongoing government initiatives and public health campaigns.
Key Takeaways:
- Market Valuation: The global varicella vaccines market is projected to grow from USD 3,258.6 million in 2024 to USD 4,115.4 million by 2034.
- Growth Momentum: The market is expected to expand at a CAGR of 2.4% during the forecast period, reflecting steady growth.
- Market Drivers: Increased public health campaigns, government vaccination initiatives, and the growing incidence of varicella infections are key factors propelling market growth.
Market Drivers
- Increased Awareness of Vaccination: Public health campaigns and government initiatives have significantly raised awareness about the effectiveness of varicella vaccination, leading to higher vaccination rates.
- Rising Incidence of Varicella Infections: The growing number of varicella infections, especially in densely populated areas, is driving demand for vaccination to prevent outbreaks.
- Government Immunization Programs: Many countries have included varicella vaccines in their routine immunization schedules, further boosting demand.
- Development of Combination Vaccines: The introduction of combination vaccines that include varicella alongside other immunizations enhances convenience for parents and increases compliance.
- Technological Advancements in Vaccine Development: Ongoing research and innovations are leading to the development of more effective and safer vaccines, which are likely to increase market growth.
Challenges
- Market Competition: The presence of various alternatives in the vaccine market can lead to pricing pressures and challenges in differentiation.
- Regulatory Hurdles: Navigating stringent regulations regarding vaccine approval and distribution can pose challenges for manufacturers.
Regional Insights
- North America: Expected to hold a significant share of the market due to high vaccination coverage and established healthcare infrastructure.
- Europe: Increasing emphasis on preventive healthcare and investments in vaccination programs will drive demand for varicella vaccines.
- Asia-Pacific: This region is poised for substantial growth driven by a large population base and expanding immunization initiatives, particularly in countries like India and China.
Competitive Landscape of the Varicella Vaccines Industry
Market players are collaborating with other industry players to augment each other’s research capability and develop novel vaccine. After the completion of a successful partnership most of the time the organizations extend the partnership program further.
Another critical area of focus is the regulatory approval process. Companies are striving to get their vaccine approved in the major market to increase their revenue stream. In order to tackle the competition large market players, acquire the small emerging biotech firm. This increases the RD portfolio of the company and help them address the upcoming competitions.
Recent Industry Developments in the Varicella Vaccines Market
- In June 2024, Sinovac biotech Ltd announced the approval of PROVARIX by China National Medical Products Administration (NMPA). It is a varicella vaccine intended to be used in patient with above 13 year of age. The two dose schedule is expected to be added to the basic immunization program.
- In October 2023, GSK plc and Chongqing Zhifei Biological Products, Ltd. signed a 3-year partnership agreement to co-promote Shingrix (GSK’s shingles vaccines) in China.
- In January 2022, BioNTech SE and Pfizer Inc. collaborated to develop and commercialize the first mRNA based vaccine for prevention of shingles.
A Comprehensive Full Report – https://www.futuremarketinsights.com/reports/varicella-vaccines-market
Key Players of the Varicella Vaccines Industry
- GlaxoSmithKline PLC
- Merck & Co. Inc.
- GC Pharma (Green Cross Holdings)
- Bio-Med Pvt Ltd
- Novo Medi Sciences Pvt Ltd
- Takeda Pharmaceutical Company Limited
- Mitsubishi Tanabe Pharma Corporation
- Sinovac Biotech Ltd.
- Changchun Keygen Biological Products Co., Ltd (CNBG Subsidiary)
- Sinergium Biotech
- SK Bioscience Co., Ltd.
Varicella Vaccines Market Segmentation
By Product:
In terms of product, the industry is segmented into monovalent vaccine and combination vaccine.
By Application:
In terms of application, the industry is bifurcated into chickenpox immunization and herpes zoster immunization.
By End User:
In terms of end users, the industry is segregated into hospitals, clinics, and others.
By Region:
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia, East Asia, the Middle East, and Africa have been covered in the report.
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
